Biomedcode is pleased to announce that, the T2EDK program -Spondylitis Evaluation Platform via non invasive Imaging Application tools (SEPIA)- initiated in collaboration with the developer of novel breakthrough imaging systems company BIOEMTECH, has been financed by the European Union and Greek national funds through the operational program Competitiveness, Entrepreneurship and Innovation under the call RESEARCH-CREATE-INNOVATE. SEPIA will combine the efforts of two innovative companies  aiming to develop precision imaging tools for the evaluation of the severity of Spondyloarthritis pathology developed in the TgA86 established mouse model of the pathology. Integration of these imaging tools in the sprondyloarthritis drug efficacy evaluation  platform will support the  preclinical development of novel therapies for Spondyloarthritis.

Biomedcode is pleased to announce that it has received funding from the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH – CREATE – INNOVATE supporting the innovative research network HUPLA that combines the efforts of industrial and renowned academic partners to develop precision drug evaluation tools  for the preclinical development of novel therapies for Multiple Sclerosis and Psoriasis. Read More

Biomedcode is pleased to announce that it has received national funding from the General Secretary for Research and Technology supporting the innovative research networks HUPLA and BreasCaRANKL that combine the efforts of industrial and renowned academic partners to develop precision drug evaluation tools  for the preclinical development of novel therapies for Multiple Sclerosis and Breast Cancer. Read More